向上滑动阅览 1. Miller JJ, et al. Isocitrate dehydrogenase (IDH) mutant gliomas: A Society for Neuro-Oncology (SNO) consensus review on diagnosis, management, and future directions. Neuro Oncol. 2023 Jan 5;25(1):4...
An orthotopic IDH-mutant murine model was generated to evaluate the role of mutant IDH on Treg infiltration by immunohistochemistry. When compared to IDH wild-type controls, Tregs are disproportionally underrepresented in mutant disease, even when taken as a proportion of all infiltrating T cells. ...
[3] Miller JJ, Gonzalez Castro LN, McBrayer S, et al. Isocitrate dehydrogenase (IDH) mutant gliomas: a Society for Neuro-Oncology (SNO) consensus review on diagnosis, management, and future directions. Neuro Oncol 2023;25:4-25. [4] Julie Grisham Monday, J. 1. (2019, July 1). Resear...
41 IDH Mutation and Oncogenesis IDH mutation is thought to be an early if not the initial event in tumorigenesis in IDH-mutant gliomas and leukemias.42,43IDH mutation appears to result in a cell state permissive of transformation. Mutation results in a profound change in the cell methylome; ...
总之,本研究为IDHm和IDHwt神经胶质瘤的代谢提供了重要的见识,并指出了突变IDH的活性迄今尚未认识到的代谢脆弱性。 Rreference :Altered metabolic landscape in IDH‐mutant gliomas affects phospholipid, energy, and oxidative stress pathwa...
6. Natsume A, et al.The first-in-human phase I study of a brain-penetrant mutant IDH1 inhibitor DS-1001 in patients with recurrent or progressive IDH1-mutant gliomas. Neuro Oncol. 2023 Feb 14;25(2):326-336. 7. de la Fuente MI, et al. Olutasidenib (FT-2102) in patients with rela...
2023年4月13日,樊小龙教授课题组在Genome Medicine(IF: 15.3)发表题为“Stalled oligodendrocyte differentiation in IDH-mutant gliomas”的研究论文,揭示了分化阻断可望成为IDH突变型胶质瘤的治疗靶点。 胶质瘤是成人中枢神经系统中最为常见的原发性颅内肿瘤。其中约50%的成人胶质瘤携带IDH突变,根据2021版WHO分类指南,...
Here we define myeloid cellular states in gliomas by longitudinal single-cell profiling and demonstrate their strict control by the tumor genotype: in isocitrate dehydrogenase (IDH)-mutant tumors, differentiation of infiltrating myeloid cells is blocked, resulting in an immature phenotype. In late-stage...
[4] Appay, Romain et al. “CDKN2A homozygous deletion is a strong adverse prognosis factor in diffuse malignant IDH-mutant gliomas.” Neuro-oncology vol. 21,12 (2019): 1519-1528. [5] Roy, David M et al. “Integrated Genomics for Pinpointing Survival Loci within Arm-Level Somatic Copy Nu...
弥漫性胶质瘤(Diffuse Gliomas)是一类侵袭性较强的脑肿瘤,其特点是肿瘤细胞向周围脑组织扩散,导致治疗中的靶区勾画变得复杂。特别是对于IDH突变2级和3级弥漫性胶质瘤,精确的放疗靶区勾画和合理的剂量处方至关重要。放疗方案的制定不仅需要考虑...